SMO and neoplasm: Taladegib binds to the extracellular end of the Smo transmembrane spiral bundle to inhibit the transmission of HH signal transduction.58 The effect of taladegib is not affected by D473 mutation, and it can effectively treat tumor cells resistant to vismodegib.378 Phase I clinical trial proved that taladegib has acceptable safety in the treatment of locally advanced and metastatic BCC patients.